Publications by authors named "Grace A Borchert"

Background: Landmark studies reported on faricimab efficacy and safety predominantly in treatment naïve patients, but outcomes following switch from other anti-VEGF therapies are lacking. We evaluated patients switched to faricimab who had previously shown a partial response to other anti-VEGF injections for neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO).

Methods: Retrospective study at the Oxford Eye Hospital.

View Article and Find Full Text PDF

Achromatopsia is the most common cone dysfunction syndrome, affecting 1 in 30,000 people. It is an autosomal recessive disorder with a heterogeneous genetic background with variants reported in , , , , , and Up to 90% of achromatopsia patients harbour mutations in or , which encode for the alpha and beta subunits of the cone cyclic nucleotide-gated (CNG) channel in cone-specific phototransduction. The condition presents at birth or early infancy with poor visual acuity, nystagmus, photophobia, and colour vision loss in all axes.

View Article and Find Full Text PDF

Background: (Cilia and Flagella Associated Protein 410) encodes a protein that has an important role in the development and function of cilia. In ophthalmology, pathogenic variants in have been described in association with cone rod dystrophy, retinitis pigmentosa, with or without macular staphyloma, or with systemic abnormalities such as skeletal dysplasia and amyotrophic lateral sclerosis. Herein, we report a consanguineous family with a novel homozygous c.

View Article and Find Full Text PDF
Article Synopsis
  • Age-related macular degeneration (AMD) is a major cause of blindness in people over 55 years old, affecting the retina and leading to central vision loss, with geographic atrophy (GA) being the most challenging subtype to treat.
  • Recent advancements in treatment include new drugs like pegcetacoplan and avacincaptad pegol, which slow GA progression but cannot reverse vision loss.
  • Optogenetics is being explored as a potential therapy by making surviving retinal cells sensitive to light, allowing for the possibility of transmitting visual information even after vision loss has occurred.
View Article and Find Full Text PDF

Background: Chronic kidney disease (CKD) increases the risk of cardiovascular disease (CVD) and is more prevalent in older adults. Retinal age gap, a biomarker of aging based on fundus images, has been previously developed and validated. This study aimed to investigate the association of retinal age gap with CKD and subsequent CVD complications.

View Article and Find Full Text PDF

Purpose: Corneal collagen crosslinking (CXL) is the primary treatment for progressive keratoconus which has a significant impact on vision and quality of life. Our study aimed to compare the efficacy and safety of epithelium-on versus epithelium-off CXL to treat keratoconus.

Methods: We searched PubMed, Medline, Embase, Web of Science, and Scopus databases.

View Article and Find Full Text PDF
Article Synopsis
  • * Current research is focused on developing therapies that target inflammation, the complement system, and neuroprotective mechanisms to slow or reverse the progression of geographic atrophy.
  • * Promising therapies, including FDA-approved complement inhibitors like pegcetacoplan and avacincaptad pegol, are being explored, along with new strategies such as optogenetic therapy, to enhance our understanding and treatment of AMD.
View Article and Find Full Text PDF

: This report describes the spontaneous extrusion from between the eyelids of a presumed conjunctivolith in a patient with resolving severe herpes zoster ophthalmicus. A 57-year-old man presented for ophthalmologic assessment and management due to severe left herpes zoster ophthalmicus. At one subsequent ophthalmologic assessment, a conjunctivolith spontaneously egressed the lateral commissure of the OS when the lateral fornix was inspected.

View Article and Find Full Text PDF

Purpose: Keratoconus is a disorder that results in visual loss from increased corneal high-order aberrations and irregular astigmatism and reduces quality of life. The primary treatment for progressive keratoconus is crosslinking (CXL). Recently, it has been suggested that oxygen enhances the type II photodynamic reaction of CXL that is oxygen dependent.

View Article and Find Full Text PDF